drugset / Trial / NCT07168291
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
Phase 0
Not yet recruiting
3 enrolled
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-lable, single arm, non-randomized study to evaluate the primary safety and efficacy of the novel bispecific AbTCR (anti-CD19/CD22)-T cells in patients with relapsed or refractory B-cell lymphoma
Timeline
- Start
- 2025-12-31
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AbTCR-T cells | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |